About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? [email protected]

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Treatment After Palbociclib-containing Regimens

NCT04517318·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Fudan University

Age

18–any

Sex

FEMALE

Healthy volunteers

Not accepted

You may be eligible if

1. woman, age \> 18 years old
2. Diagnosed with HR+/HER2- Metastatic Breast Cancer
3. Patients received at least one-cycle next-line treatment after progression on combined palbociclib and endocrine therapy
4. Complete medical history was available

You may not be if

1\. Medical history was incomplete

The record

StatusCompleted

PhaseNo phase

Taking part200

StartedAug 2017

UpdatedAug 3, 2021

Conditions

Where1

Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China

Clareo Health | Treatment After Palbociclib-containing Regimens